- Home
- NBBK vs ATXS Comparison
NBBK vs ATXS Comparison
Compare NBBK & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBBK | ATXS |
|---|---|---|
| Founded | 1892 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 718.5M | 732.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NBBK | ATXS |
|---|---|---|
| Price | $21.40 | $12.82 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 6 |
| Target Price | $23.00 | ★ $24.33 |
| AVG Volume (30 Days) | 256.4K | ★ 1.5M |
| Earning Date | 01-21-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ 420.99 | N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $189,481,000.00 | $706,000.00 |
| Revenue This Year | $43.56 | N/A |
| Revenue Next Year | $23.60 | N/A |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | ★ 30.69 | N/A |
| 52 Week Low | $15.09 | $3.56 |
| 52 Week High | $21.58 | $13.29 |
Technical Indicators
Market Signals| Indicator | NBBK | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 70.09 | 58.66 |
| Support Level | $20.72 | $12.64 |
| Resistance Level | $21.58 | $12.92 |
| Average True Range (ATR) | 0.41 | 0.24 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 83.62 | 31.06 |
Price Performance
Historical ComparisonAbout NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.